ArriVent BioPharma, Inc. Income Statement
AVBP / Health Care|2 years of annual SEC 10-K data (FY2023-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 |
|---|---|---|
| SG&A Expense | $15.3M | $9.7M |
| R&D Expense | $79.0M | $64.9M |
| Operating Income | -$94.3M | -$74.6M |
| Net Income | -$80.5M | -$69.3M |
| EPS (Basic) | -$2.56 | -$32.38 |
| EPS (Diluted) | -$2.56 | -$32.38 |
| Shares Outstanding | 31.5M | 2.1M |